Barclays’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Barclays’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-600	Closed	-$7K	–	7455
2019 Q1	$7K	Buy	+600	New	+$8.02K	﹤0.01%	6657
2018 Q2	–	Sell	-700	Closed	-$16K	–	7438
2018 Q1	$16K	Buy	+700	New	+$17.1K	﹤0.01%	6514
2015 Q4	–	Sell	-225,000	Closed	-$3.15M	–	6796
2015 Q3	$3.15M	Buy	+225,000	New	+$5.28M	﹤0.01%	1728

Barclays's FLXN Position: Q4 2021 in Review

Barclays sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 100,547 shares — an estimated $614K sold.

Barclays first reported a position in FLXN in Q1 2014 and held it in 31 quarters. The position peaked at $3.64M in Q4 2019. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Barclays reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Barclays sold 100,547 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $614K.
Barclays first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
Barclays's Flexion Therapeutics, Inc. position peaked at $3.64M in Q4 2019.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.